HeraMED turns Lee Health pilot into paid US deployment as commercial model starts to take shape

HeraMED has crossed an important commercial threshold in the United States, with Lee Health approving a full-scale deployment of the company’s digital maternity platform following a successful six-month pilot.

The distinction matters. Digital health companies can spend years accumulating pilots, trials and memorandums of understanding without converting them into material revenue. HeraMED now has a paid deployment with one of Southwest Florida’s major healthcare systems, moving the relationship from clinical validation into commercial execution.

Lee Health is a roughly US$3 billion non-profit healthcare system delivering more than 8,000 babies annually and managing around 2,000 active pregnancies at any given time. The first stage of the scale-up will cover another 200 pregnant women, under a Statement of Work worth US$317,200.

That contract includes 200 twelve-month HeraCARE licences, 200 maternity monitoring kits, implementation work, Epic electronic medical record integration, logistics, and device and application support.

On a simple basis, that works out at about US$1,586 per participating mother. Investors should be cautious about treating that figure as recurring software revenue, however, because the initial contract also contains hardware and implementation components. The more important development is that HeraCARE has been accepted under a recurring, 12-month-per-mother SaaS pricing structure.

Pilot metrics provide the commercial foundation

The deployment follows encouraging results from Lee Health’s pilot program.

HeraMED reported 92 per cent virtual adoption, a 100 per cent likelihood to recommend the program, a program Net Promoter Score of 60 and an NPS of 75 for its remote patient monitoring devices.

The model allowed prenatal care to be delivered through an 11-visit digital-first pathway, compared with approximately 15 in-person visits under the traditional approach, while maintaining the existing standard of care.

For health systems, that potential reduction in physical appointments is commercially relevant. Maternity care faces the same pressures affecting healthcare more broadly: clinician shortages, rising costs and increasing demand for services that can be delivered remotely without compromising patient oversight.

The next phase will combine the HeraCARE patient application and clinician dashboards with HeraBEAT at-home fetal heart rate monitors, connected blood pressure devices and four customised prenatal and postpartum care plans.

Epic integration could prove strategically important

One of the less glamorous but potentially more significant aspects of the Lee Health deployment is integration with Epic, the electronic medical record system already used by Lee Health clinicians.

Digital health products can struggle when they create additional workflows for doctors and nurses. Embedding HeraCARE into an existing clinical record system should reduce that friction and may strengthen HeraMED’s proposition when approaching other large US health systems.

Managing director and chief executive Anoushka Gungadin described the deployment as the point at which HeraMED moves from a successful first phase into "full-scale commercial deployment" with a major health system.

She also highlighted Epic integration as a key milestone because HeraCARE will sit inside the record clinicians already use, with the aim of reducing administrative workload while improving the patient experience.

Lee Health chief physician executive and vice president of Women’s Services Dr Cherrie Morris said the organisation was focused on delivering maternity care in ways that worked for patients, combining technology with traditional services while maintaining access to care and support.

Expansion mechanism creates room for recurring growth

The initial 200 mothers are only the starting cohort.

Once those licences have been activated, Lee Health can order additional patient bundles in increments of 20, 50, 100 or larger groups, with each expansion attracting additional fees.

That structure gives investors a clearer framework for assessing future commercial traction. Instead of relying purely on new hospital wins, HeraMED now has the possibility of growing revenue inside an existing health system as more clinics and care teams are onboarded.

The scale of Lee Health also provides meaningful headroom. The group handles more than 8,000 births each year, so the first 200-patient deployment represents only a modest proportion of the potential addressable population within the system.

The relationship initially covers four pathways: low-risk prenatal care, hypertension in pregnancy, postpartum care and patient engagement. There is also scope to extend the platform into additional women’s health services.

Execution now becomes the key test

Commercial approval does not remove execution risk.

HeraMED must still finalise implementation planning, onboard clinics, complete Epic integration and demonstrate that patient enrolment can ramp smoothly across the Lee Health network. Investors will also want greater visibility over the revenue split between recurring software, hardware and implementation services as the deployment matures.

Nevertheless, the shift from pilot to paid deployment addresses one of the central questions surrounding early-stage digital health companies: whether positive clinical engagement can translate into repeatable commercial contracts.

HeraMED is now applying the Lee Health model to its broader US pipeline, including opportunities through channel partner Philips and potential participation in initiatives associated with the US$50 billion Rural Health Transformation Program.

For investors, the next markers will be operational rather than promotional: the pace at which the first 200 patients are onboarded, subsequent licence orders from Lee Health, progress with Epic integration and evidence that the same sales model can be replicated across other US healthcare systems.